HR+/HER2-晚期乳腺癌患者内分泌治疗的临床效果及预后影响因素分析  

Analysis of Clinical Efficacy and Prognostic Factors of Endocrine Therapy in Patients with HR+/HER2-Advanced Breast Cancer

作　　者：谢文聪 黄钰 卢少彩 XIE Wenchong;HUANG Yu;LU Shaocai(Henan Third People's Hospital,Zhengzhou,450000)

机构地区：[1]河南省直第三人民医院,450000

出　　处：《实用癌症杂志》2024年第7期1137-1140,共4页The Practical Journal of Cancer

摘　　要：目的 观察内分泌治疗HR+/HER2-晚期乳腺癌患者的临床效果,并探讨影响预后的因素。方法 选取120例HR+/HER2-晚期乳腺癌患者,所有患者均给予内分泌治疗。治疗后评估治疗效果,记录不良事件的发生情况。对患者进行为期1年的随访,根据患者有无复发及转移分为预后不良组及预后良好组。收集患者资料,单因素及多因素Logistic回归分析影响HR+/HER2-晚期乳腺癌患者预后的因素。结果 120例HR+/HER2-晚期乳腺癌患者治疗后达到CR 2例(1.67%),PR 15例(12.50%)。随访1年后,21例患者出现复发或转移,99例未出现复发及转移。不良事件中中性粒细胞减少发生率为97.50%(117/120)、白细胞减少发生率为93.33%(112/120),其中以2~3级占比最高,通过调整用药剂量可缓解不良事件。非血液学不良事件中乏力最为常见,占23.33%(28/120);其次为口腔黏膜炎9.17%(11/120)。不同预后组间患者年龄、是否内脏转移及既往化疗线数比较具有明显差异(P<0.05);将具有差异的因素纳入行多因素Logistic回归分析显示,年龄、内脏转移及既往二、三线化疗为影响HR+/HER2-晚期乳腺癌患者预后的因素(P<0.05)。结论 内分泌治疗HR+/HER2-晚期乳腺癌较为安全有效,患者年龄、内脏转移及既往2-3线化疗为影响患者预后的因素。Objective To observe the clinical efficacy of endocrine therapy in patients with HR+/HER2-advanced breast cancer and to explore the factors affecting prognosis.Methods A total of 120 patients with HR+/HER2-advanced breast cancer were enrolled,and all patients were given endocrine therapy,the treatment effect after treatment was evaluated,and the occurrence of adverse events was recorded.The patients were followed up for 1 year,and the patients were divided into poor prognosis group and good prognosis group according to whether patients had recurrence and metastasis.Patient data were collected,and univariate and multivariate logistic regression was analyzed for factors affecting the prognosis of HR+/HER2-advanced breast cancer patients.Results Of the 120 patients with HR+/HER2-advanced breast cancer,2 cases(1.67%)reached CR and 15 cases(12.50%)reached PR after treatment.After 1 year of follow-up,21 patients had recurrence or metastasis,and 99 patients had no recurrence or metastasis.The incidence of neutropenia in adverse events was 97.50%(117/120),the incidence of leukopenia was 93.33%(112/120).Among which grade 2-3 accounted for the highest proportion,and the adverse events could be alleviated by adjusting the dosage.Among the non-hematologic adverse events,fatigue was the most common at 23.33%(28/120),followed by oral mucositis at 9.17%(11/120).There were significant differences in age,visceral metastasis,and number of previous chemotherapy lines between different prognostic groups(P<0.05).Multivariate logistic regression analysis showed that age,visceral metastases,and prior 2-3 lines of chemotherapy were factors affecting the prognosis of patients with HR+/HER2-advanced breast cancer(P<0.05).Conclusion Endocrine therapy is safe and effective in patients with HR+/HER2-advanced breast cancer,and age,visceral metastasis and previous 2-3 lines of chemotherapy are the factors affecting the prognosis of patients.

关 键 词：HR+/HER2-晚期乳腺癌 内分泌治疗 预后 疗效 

分 类 号：R737.9[医药卫生—肿瘤]